Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer.

Molecular cancer therapeutics - 1 Jan 2011

Villarroel Maria C, Rajeshkumar N V, Garrido-Laguna Ignacio, De Jesus-Acosta Ana, Jones Siân, Maitra Anirban, Hruban Ralph H, Eshleman James R, Klein Alison, Laheru Daniel, Donehower Ross, Hidalgo Manuel

Abstract excerpt

Metastasis and drug resistance are the major causes of mortality in patients with pancreatic cancer. Once developed, the progression of pancreatic cancer metastasis is virtually unstoppable with current therapies. Here, we report the remarkable clinical outcome of a patient with advanced, gemcita...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Deoxycytidine
Share to DNA Breaks, Double-Stranded

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fanconi Anemia Complementation Group N Protein

Share to Gemcitabine

Share to Mice, Nude

Share to Mitomycin

Share to Pancreatic Neoplasms

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 21135251
DOI: 10.1158/1535-7163.MCT-10-0893
PMCID: PMC3307340

Genes

PALB2
BRCA1
BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-21135251-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer.PMID 21135251Read ↗

Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene.Semantic proximity Read ↗

Smaller panel, similar results: genomic profiling and molecularly informed therapy in pancreatic cancerSemantic proximity Read ↗

Personalizing Medicine With Germline and Somatic Sequencing in Advanced Pancreatic Cancer: Current Treatments and Novel OpportunitiesSemantic proximity Read ↗

A Somatic BRCA2-Mutated Pancreatic Adenocarcinoma With Sustained Exceptional Response to Modified FOLFIRINOXSemantic proximity Read ↗

Integrated Patient-Derived Models Delineate Individualized Therapeutic Vulnerabilities of Pancreatic CancerSemantic proximity Read ↗

Pancreas cancer and BRCA : A critical subset of patients with improving therapeutic outcomesSemantic proximity Read ↗

Germline DNA Sequencing Reveals Novel Mutations Predictive of Overall Survival in a Cohort of Patients with Pancreatic Cancer.Semantic proximity Read ↗

Pancreatic cancer: BRCA mutation and personalized treatment.Semantic proximity Read ↗

Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical Phenotype.Semantic proximity Read ↗

Precision Medicine for BRCA/PALB2-Mutated Pancreatic Cancer and Emerging Strategies to Improve Therapeutic Responses to PARP InhibitionSemantic proximity Read ↗

Recapitulating the clinical scenario of BRCA-associated pancreatic cancer in pre-clinical models.Semantic proximity Read ↗

Targeting DNA Damage Repair Pathways in Pancreatic Adenocarcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.